Delta-Vir GmbH
Immunotherapeutics

A new paradigm
for the therapy of cancer patients

At Delta-Vir we believe that "Quality counts and life is for living!"

We believe that cancer therapeutics should not only significantly extend the life expectancy of cancer sufferers, but that the treatment should not have side effects which further decrease the patients’ general well-being and quality of life.  Our cancer vaccine is such that it can be used concomitantly with standard radio/chemotherapy treatments but also has the future potential to be used as a standalone therapy.


The company Delta-Vir GmbH was founded in 2011 with the  aim of expanding the access of a novel therapeutic cancer vaccine treatment which has been developed and used to treat patients at the IOZK (Immunologisches und Onkologisches Zentrum Köln) in Cologne, Germany.

Our cancer treatment is based on use of an anti-cancer vaccine which specifically stimulates the patient's own immune response to fight their tumour. This type of vaccine is unusual in that being a bespoke, patient-specific therapy it has been devised to provide a uniquely appropriate and specific response to the actual tumour tissue which affects the patient.

Dendritic Cell Vaccines

The award of the 2011 Nobel Prize for Medicine for the discovery of dendritic cells and the understanding of the activation and control of the immune system highlights the potential for future scientific breakthrough in this area. Our dendritic cell vaccine work over past decade has built on these discoveries and attempts to apply this knowledge to develop an effective immunological approach to cancer therapy.


may 06 2013

Delta-Vir's dossier on their vaccine product for the treatment of Glioblastoma was accepted by the European Medicines Agency for scientific advice.


february 01 2013

Delta-Vir has expanded its clinical capability by recruiting 3 new members of staff, including experienced Clinical Research Associates and a Clinical Project Manager, who will work closely with our partners to develop our clinical protocol and assessment of potential study sites.


december 11 2012

The Orphan Drug Designation Application for Delta-Vir’s product for the treatment of Glioblastoma was initiated and presented to the Committee for Orphan Medicinal Products of the European Medicines Agency at a pre-submission meeting.


july 02 2012

Delta-Vir GmbH has recently signed a contract to rent GMP and R&D laboratory facilities situated in the BIOCITY Leipzig Center for Biotechnology and Biomedicine.